FIELD: biotechnology, veterinary science. SUBSTANCE: invention proposes medicinal form of highly purified immunologically active preparation based on hybrid protein T-TNF-T. Hybrid protein T-TNF-T is isolated from microorganism where recombinant plasmid pThy325 encoding protein biosynthesis is inserted. Preparation has the following components, wt.-%: hybrid protein 0.0008-0.0015; stabilizing additions 10-20, saline buffer system at pH = 7.0-7.2 1.03-1.06, and water - the rest. Polyglucine, gelatinol, sucrose were used as stabilizing additions and buffered sodium chloride physiological solution - as saline buffer system. Preparation can be used for nonspecific prophylaxis and treatment of infectious diseases. EFFECT: enhanced effectiveness of preparation. 3 cl, 6 tbl
Title | Year | Author | Number |
---|---|---|---|
VACCINES BASED ON VIRUS-LIKE PARTICLES (VLP) OF CANINE PARVOVIRUS (CPV) AND APPLICATION THEREOF | 2016 |
|
RU2710854C1 |
IMMUNOMODULATING PREPARATION "NEOFERON" SHOWING ANTIVIRAL ACTIVITY | 1996 |
|
RU2129878C1 |
IMMUNOGENIC COMPOSITIONS OF GLYCOPROTEIN G OF HENDRA AND NIPAH VIRUSES | 2012 |
|
RU2787820C2 |
SINGLE-DOMAIN ANTIBODIES AGAINST INTRACELLULAR ANTIGENS | 2015 |
|
RU2810002C2 |
VACCINATION USING THE ALPHA 3 DOMAIN OF MICA/B FOR CANCER TREATMENT | 2016 |
|
RU2747296C2 |
IMMUNE-INDUCING AGENT | 2017 |
|
RU2777992C2 |
ADVANCED CORONAVIRUS VACCINE | 2022 |
|
RU2816182C2 |
COMPOSITION FOR STIMULATING DENDRITIC CELL MATURATION, CONTAINING HYBRID PROTEIN RV2299C/ESAT-6 | 2017 |
|
RU2733886C2 |
INFLUENZA VIRUS CAPABLE OF INFECTING CANINES AND ITS USE | 2020 |
|
RU2802222C2 |
PROTEIN AND VACCINE AGAINST SARS-CoV-2 INFECTION | 2020 |
|
RU2815060C1 |
Authors
Dates
1998-01-27—Published
1995-02-10—Filed